5-FU
June 8, 2015

Saladax Biomedical, Inc. Announces the Presentation of the CESAR Study Results for Pharmacokinetically-Guided Dosing of 5-Fluorouracil in Colorectal Cancer at 2015 ASCO Meeting

Advantages of a Practical Approach to Personalized Dosing of 5-FU Demonstrated Saladax Biomedical, Inc. recently…
Read More